Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05623007

Dietary Modulation of Gut Microbiota in Overweight/Obese Adolescents and COVID-19 Infection

Probiotic intervention has been currently suggested to provide supportive benefits in promoting health, including alleviating disease symptoms, protecting against diarrhea and respiratory infection, affecting growth and modulating the immune system by improving the beneficial gut microbiota colonization, giving direction on the gut-lung-axis pathway. This indicates that probiotics may become alternative to improve nutrition and reduce the risk of viral infections which may reduce the risk against Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). Introduction to probiotics during adolescence can alleviate inflammation and invert dysbiosis. However, evidence on the effect of probiotic supplementation on enhancing antibody response to SARS COV-2 in adolescents is lacking. Moreover, previous studies showed the potential effect of probiotic supplementation to improve overweight and obesity in adolescents. A bi-directional relationship exists among nutrition, infection, and immunity as changes in one element will affect the others. The main objective of this study is to investigate the effect of dietary modulation of overweight and obese adolescent's gut microbiota through probiotic supplementation combined with healthy eating and physical activity counseling and psychosocial stimulation on nutritional status and antibody response to COVID-19 vaccination. This trial will conduct a 20-week intervention for overweight and obese adolescents.

Recruiting

Interested in participating?

Request Info

Key information

Age range

12 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Nutrition (FKUI-RSCM); and Human Nutrition Research Center, Indonesian Medical Education Research Institute (HNRC-IMERI) Faculty of Medicine, Universitas Indonesia

Jakarta Pusat, DKI Jakarta, 10430, Indonesia

Location status: Recruiting

Location contact

Adi Pranoto, MKes

SUB_INVESTIGATOR

Ainun Nisa, SGz

SUB_INVESTIGATOR

Alfi R Putri, MSc

SUB_INVESTIGATOR

Alpha F Athiyyah, PhD

SUB_INVESTIGATOR

Dian N Chandra, PhD

SUB_INVESTIGATOR

Dwi Susanti, PhD

SUB_INVESTIGATOR

Dwiana Ocviyanti, PhD

SUB_INVESTIGATOR

Emy Huriyati, PhD

SUB_INVESTIGATOR

Erfi Prafiantini, MSc

SUB_INVESTIGATOR

Fhadilla Amelia, MSc

SUB_INVESTIGATOR

Julie Bines, PhD

SUB_INVESTIGATOR

Karina R Ekawidyani, PhD

SUB_INVESTIGATOR

Lilik Djuari, PhD

SUB_INVESTIGATOR

Mira Mutiyani, MSc

SUB_INVESTIGATOR

Mohammad Juffrie, PhD

SUB_INVESTIGATOR

Murdani Abdullah, PhD

SUB_INVESTIGATOR

Purwo S Rejeki, PhD

SUB_INVESTIGATOR

Rina Agustina, PhD

CONTACT

[email protected]

+6221 2912477

Rina Agustina, PhD

PRINCIPAL_INVESTIGATOR

Susan Sawyer, PhD

SUB_INVESTIGATOR

Triska S Nindya, PhD

SUB_INVESTIGATOR

Wahyu Damayanti, MSc

SUB_INVESTIGATOR

About this study

The adolescence period is the transition from childhood to adulthood. Adolescents are vulnerable to many biomedical exposures, such as a low-quality diet, fewer fruits and vegetable intake, low physical activities, smoking habits, and alcohol consumption; and non-biomedical aspects such as mental depression, parental distress, and household income, which were known to be associated with increased risk of many health outcomes. Obese adolescents are vulnerable to many infections, poor disease outcomes and complications, and lower antibody response to vaccinations. Studies that have investigated Covid-19 incidence in overweight and obese individuals are still scarce. Adolescence is also a sensitive period to microbial change or dysbiosis due to practicing poor diet, low physical activity, inadequate sleep, stress, and substance use (smoking, drugs, and alcohol). Despite the existing prevalence of SARS-COV-2 infections is increasing in adolescents, and the vaccine program is not prioritized in this population, making the prevention strategy for SARS-COV-2 infection may become less effective in this population. Besides, low-quality diet and lifestyle habits and family cluster transmission at home are often not fully addressed in the policy. These factors may be the contributors to the potential highest COVID-19 exposure for children and adolescents. Since exposure among adolescents is linked to serious adverse health effects, effective interventions to improve nutritional outcomes and reduce the risk of COVID-19 infection will provide substantial long-term returns. However, such interventions for adolescents in Indonesia and globally are lacking.

This study is a randomized clinical trial (RCT) and placebo parallel controlled study. The research will be conducted in junior and senior high schools in Jakarta, Surabaya, and Yogyakarta, Indonesia.

In light of COVID-19 outbreak, if face-to-face activities are permitted by (1) national government (Indonesian Ministry of Health), (2) local government (DKI Jakarta), (3) the university, (4) Data Safety Monitoring Board, and (5) by consent of the subject, then the activities need to be strictly adjusted with the COVID-19 prevention measures for both personnel and subjects. All personnel and subjects who will be involved in the activities are required to fill out the COVID-19 symptom screening form prior to the visit and have been vaccinated with a complete dose.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • living in Jakarta, Surabaya, and Yogyakarta City for at least 6 months permanently;
  • apparently healthy;
  • male and female, age 12-17 years old;
  • overweight or obese (BMI-for-age z-score >+1SD);
  • have completed at least two dosages of COVID-19 vaccine, the vaccine must be CoronaVac® (Sinovac);
  • minimal 6 months post vaccinated prior to recruitments.
  • parents willing to sign the informed consent and adolescents give informed assent;
  • Must have an active health insurance, for instance BPJS or similar health insurance.

Exclusion criteria

  • having a history of COVID-19 infection within the last month confirmed by PCR or antigen from health care facilities or independent laboratory;
  • having a history of chronic and non-communicable diseases, congenital diseases, and disabilities;
  • reported current diagnosed as suspected active Tuberculosis (primary lung TB, miliary TB, bleeding cough bone TB, meningitis TB);
  • having a history of gastrointestinal or malabsorption disorder (such as celiac disease and inflammatory bowel disease) within the last three months or during the study;
  • taking antibiotics during 2 weeks before the start of the study (adolescents will be included after 3 weeks of last antibiotic intake);
  • taking other medications or having diseases that may influence the immune response - i.e. immune deficiencies, immunosuppressants medications, blood transfusion or other blood products;
  • taking insulin and/or anti-dyslipidemia medication;
  • being pregnant and/or breastfeeding.

Treatment and study plan

Probiotics

Dietary Supplement

Combination of 3 probiotic strains: Lactobacillus rhamnosus (LGG), Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (LA-5)

Counselling on healthy eating, physical activity, and psychosocial stimulation

Behavioral

Counselling on healthy eating, physical activity, and psychosocial stimulation.

Placebo probiotics

Dietary Supplement

Maltodextrin

Primary outcomes

  1. BMI-for-age z-scores (BAZ)

    Time frame: 5, 10, 15, and 20 weeks

    Change in BAZ obtain from anthropometric measurements, i.e., weight (kg) and height (m) converted to BMI

  2. Immunoglobulin G (IgG) specific to SARS-COV-2 titer concentrations

    Time frame: 10 and 20 weeks

    Change in IgG specific to SARS-COV-2 titer concentrations assessed by electro chemiluminescence immunoassay (ECLIA)

Secondary outcomes

  1. α-gut microbiota diversity

    Time frame: 20 weeks

    Change in α-diversity measured by 1) Chao1, 2) phylogenetic diversity, and 3) the Shannon index.

  2. β-gut microbiota diversity

    Time frame: 20 weeks

    Change in β -diversity: as the variability in community composition (the identity of taxa observed) among samples

  3. Monoclonal antibody affinity against SARS-COV-2

    Time frame: 10 and 20 weeks

    Change in equilibrium dissociation constant (KD) of monoclonal antibody against SARS-COV-2 spike protein measured by competitive ELISA

  4. Secretory Immunoglobulin A (sIgA) specific to SARS-COV-2 titer concentrations

    Time frame: 10 and 20 weeks

    Change in sIgA specific to SARS-COV-2 titer concentrations assessed by competitive ELISA

  5. Dietary quality

    Time frame: 5, 10, 15, and 20 weeks

    Change in score of dietary quality assessed by Healthy Eating Index 2015 from 24 hour recalls data

Other outcomes

  1. SARS-COV-2 infection

    Time frame: 20 weeks

    Changes in proportion of symptomatic COVID-19 and positive PCR

  2. Body height

    Time frame: 5, 10, 15, and 20 weeks

    Changes in height-for-age z-score by anthropometric measurement

  3. Abdominal obesity (waist circumference)

    Time frame: 5, 10, 15, and 20 weeks

    Changes in waist circumference by anthropometric measurement

  4. Abdominal obesity (waist-hip ratio)

    Time frame: 5, 10, 15, and 20 weeks

    Changes in waist-hip ratio by anthropometric measurement

  5. Middle upper arm circumference

    Time frame: 5, 10, 15, and 20 weeks

    Changes in middle upper arm circumference by anthropometric measurement

  6. Immunoglobulin M (IgM) against SARS-Cov-2

    Time frame: 10 and 20 weeks

    Changes in IgM titer concentrations assessed by electro chemiluminescence immunoassay (ECLIA)

  7. Neutralizing antibody against SARS-Cov-2

    Time frame: 10 and 20 weeks

    Changes in total neutralizing antibody titer assessed by Surrogate Virus Neutralization Test (sVNT)

  8. Gut integrity (zonulin)

    Time frame: 20 weeks

    Changes in the level of serum zonulin assessed by ELISA and Changes in the level of fecal zonulin assessed by ELISA

  9. Gut integrity (occludin)

    Time frame: 20 weeks

    Changes in the level of fecal occludin assessed by ELISA

  10. Gut inflammation

    Time frame: 20 weeks

    Changes in concentration of fecal calprotectin assessed by ELISA

  11. Gut microbiota profiling

    Time frame: 20 weeks

    Changes in composition of gut microbiota assessed by next-generation sequencing (NGS)

  12. Short Chain Fatty Acids (SCFA)

    Time frame: 20 weeks

    Change in concentration of the SCFA by gas chromatograph

  13. Physical activity

    Time frame: 5, 10, 15, and 20 weeks

    Changes in International Physical Activity Questionnaire for Adolescent (IPAQ-A) score, the minimum is 0 metabolic equivalents of task (MET) minutes/week, and the maximum score is 3000 MET minutes/week. Higher score means better outcome.

  14. Body image

    Time frame: 20 weeks

    Changes in Body Shape Questionnaire-34 (BSQ-34) score. The minimum score is 34, and the maximum is 204. Higher score means worse outcome

  15. Depression

    Time frame: 20 weeks

    Changes in Patient Health Questionnaire for Adolescents (PHQ-A) score. The minimum score is 0, and the maximum is 27. Higher scores mean worse outcome.

  16. Self-esteem

    Time frame: 20 weeks

    Changes in Rosenberg Self Esteem Scale. The minimum score is 0, and the maximum score is 37. Higher scores mean better outcome.

  17. Quality of life score

    Time frame: 20 weeks

    Changes in the score of Youth Quality of Life for adolescents-Research version (YQOL-R). The minimum score is 0, and the maximum score is 100. Higher scores mean better outcome.

  18. Morbidity

    Time frame: 5, 10, 15, and 20 weeks

    Type and frequency of illness

  19. Mortality

    Time frame: 5, 10, 15, and 20 weeks

    Type and frequency of illness

  20. Wechsler Intelligence Scale for Children score

    Time frame: 20 weeks

    Changes in Wechsler Intelligence Scale for Children (WISC). The minimum score is 70, and the maximum score is 159. Higher scores mean better outcome.

  21. Brain Derived Neurotropic Factor level

    Time frame: 20 weeks

    Changes in level of Brain Derived Neurotropic Factor (BDNF) assessed by ELISA

  22. Anemia status

    Time frame: 20 weeks

    Changes in hemoglobin concentration

Study contacts

Contact information is provided by the study sponsor or research team.

Rahyussalim Rahyussalim, PhD

CONTACT

[email protected]

+622129189160 ext. 201908

Rina Agustina, PhD

CONTACT

[email protected]

+622129189160 ext. 201052

Sponsors and collaborators

Lead sponsor

Indonesia University

Other

Collaborators

  • Gadjah Mada University
  • The Indonesia Endowment Funds for Education, Ministry of Finance Indonesia
  • Universitas Airlangga
  • University of Melbourne

Registry information

Official study title

Dietary Modulation of Gut Microbiota on Nutritional Status and COVID-19 Infection in Adolescents: Gut-Lung-Axis

Acronym: DIVINE

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Nov 21, 2022
Registry last updated
Feb 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.